NIH Grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403

Cancer Targeted Technology announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research Phase IIB grant.
[Cancer Targeted Technology (Business Wire, Inc.)]
Press Release

Continue reading “NIH Grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403”

Bookmark

No account yet? Register

0
Share

BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute

BryoLogyx, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia and lymphoma.
[BryoLogyx, Inc.]
Press Release

Continue reading “BryoLogyx Announces Cooperative Research and Development Agreement for Bryostatin-1 with National Cancer Institute”

Bookmark

No account yet? Register

0
Share

Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration with AstraZeneca to evaluate the combination of patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate, and TAGRISSO, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer.
[Daiichi Sankyo Company, Limited]
Press Release

Continue reading “Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer”

Bookmark

No account yet? Register

0
Share

MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation

MODAG announced the successful completion of its first clinical trial of anle138b (NCT04208152) in healthy volunteers. Based on the positive Phase I study results, MODAG was also able to obtain additional funding of USD 1.4 million from The Michael J. Fox Foundation for parkinson’s research.
[MODAG]
Press Release

Continue reading “MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation”

Bookmark

No account yet? Register

0
Share

Cynata Completes Phase I GvHD Clinical Trial Follow-up with Positive Results

Cynata Therapeutics Ltd. has announced positive results from the two-year follow-up of patients enrolled in the Phase I clinical trial of CYP-001, Cynata’s lead iPSC-derived Cymerus™ mesenchymal stem cell product.
[Cynata Therapeutics Inc.]
Press Release

Continue reading “Cynata Completes Phase I GvHD Clinical Trial Follow-up with Positive Results”

Bookmark

No account yet? Register

0
Share

Heart Regeneration using Pluripotent Stem Cells

In this review, the authors summarize the updated knowledge, perspectives, and limitations of PSC-derived cardiomyocytes for heart regeneration.
[Journal of Cardiology]
Kadota, S., Tanaka, Y., & Shiba, Y. (2020). Heart regeneration using pluripotent stem cells. Journal of Cardiology, 0(0). https://doi.org/10.1016/j.jjcc.2020.03.013 Cite
Abstract

Continue reading “Heart Regeneration using Pluripotent Stem Cells”

Bookmark

No account yet? Register

0
Share

China’s Coronavirus Vaccines Are Leaping Ahead – but Face Challenges as Virus Wanes

Chinese companies are at the forefront of global efforts to create a vaccine for the coronavirus, with more than half a dozen candidates in clinical development. Yet the companies could face difficulty as they try to push vaccines through phase III trials, a crucial stage of testing that is needed to prove efficacy and secure approval from regulators.
[Nature News]
Press Release

Continue reading “China’s Coronavirus Vaccines Are Leaping Ahead – but Face Challenges as Virus Wanes”

Bookmark

No account yet? Register

0
Share

Cleave Therapeutics Announces Commencement of a Phase I Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Cleave Therapeutics, Inc. announced that the first patient has been dosed with CB-5339 in a Phase I clinical trial of patients with relapsed/refractory AML or relapsed/refractory intermediate or high-risk MDS.
[Cleave Therapeutics, Inc.]
Press Release

Continue reading “Cleave Therapeutics Announces Commencement of a Phase I Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)”

Bookmark

No account yet? Register

0
Share

Heart Regeneration Using Pluripotent Stem Cells

In this review, the authors summarize the updated knowledge, perspectives, and limitations of PSC-derived cardiomyocytes for heart regeneration.
[Journal of Cardiology]
Kadota, S., Tanaka, Y., & Shiba, Y. (2020). Heart regeneration using pluripotent stem cells. Journal of Cardiology, 0(0). https://doi.org/10.1016/j.jjcc.2020.03.013 Cite
Abstract

Continue reading “Heart Regeneration Using Pluripotent Stem Cells”

Bookmark

No account yet? Register

0
Share

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies

Researchers discuss innovative developments in the CAR T-cell therapy field that benefited from evaluation in humanized mice, illustrated by multiple examples.
[Cancers]
Full Article

Continue reading “Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies”

Bookmark

No account yet? Register

0
Share

Subarachnoid Transplantation of Human Umbilical Cord Mesenchymal Stem Cell in Rodent Model with Subacute Incomplete Spinal Cord Injury: Preclinical Safety and Efficacy Study

The authors performed cellular, kinematic, physiological, and anatomical analyses, either in vitro or in vivo, to comprehensively evaluate the safety and efficacy associated with subarachnoid transplantation of human umbilical cord mesenchymal stem cells in rats with subacute incomplete spinal cord injury.
[Experimental Cell Research]
Yang, Y., Cao, T.-T., Tian, Z.-M., Gao, H., Wen, H.-Q., Pang, M., He, W.-J., Wang, N.-X., Chen, Y.-Y., Wang, Y., Li, H., Lin, J.-W., Kang, Z., Li, M.-M., Liu, B., & Rong, L.-M. (2020). Subarachnoid transplantation of human umbilical cord mesenchymal stem cell in rodent model with subacute incomplete spinal cord injury: Preclinical safety and efficacy study. Experimental Cell Research, 112184. https://doi.org/10.1016/j.yexcr.2020.112184 Cite
Abstract

Continue reading “Subarachnoid Transplantation of Human Umbilical Cord Mesenchymal Stem Cell in Rodent Model with Subacute Incomplete Spinal Cord Injury: Preclinical Safety and Efficacy Study”

Bookmark

No account yet? Register

0
Share

Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT Study, a Phase IIa Clinical Trial of TERN-101 in Development for NASH

Terns Pharmaceuticals, Inc., has announced that it has dosed the first patient in the LIFT study, a Phase IIa clinical trial of TERN-101, a liver-selective farnesoid X receptor agonist, the company’s lead development candidate for the treatment of non-alcoholic steatohepatitis (NASH).
[Terns Pharmaceuticals]
Press Release

Continue reading “Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT Study, a Phase IIa Clinical Trial of TERN-101 in Development for NASH”

Bookmark

No account yet? Register

0
Share
Share